HF
LCTX icon

HRT Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

HRT Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-232,264
Closed -$366K – 4835
2026
Q1 		$366K Buy
+232,264
New +$392K ﹤0.01% 2734
2025
Q3 		– Sell
-280,077
Closed -$254K – 3303
2025
Q2 		$254K Buy
280,077
+71,159
+34% +$42.2K ﹤0.01% 1946
2025
Q1 		$94K Buy
+208,918
New +$123K ﹤0.01% 2156
2024
Q1 		– Sell
-35,923
Closed -$39K – 2734
2023
Q4 		$39K Buy
+35,923
New +$39.4K ﹤0.01% 1977
2023
Q3 		– Sell
-744,628
Closed -$1.05M – 2786
2023
Q2 		$1.05M Buy
744,628
+495,248
+199% +$684K 0.01% 925
2023
Q1 		$374K Buy
249,380
+229,171
+1,134% +$320K ﹤0.01% 1579
2022
Q4 		$23K Buy
+20,209
New +$25.5K ﹤0.01% 2168
2022
Q1 		– Sell
-135,074
Closed -$330K – 3498
2021
Q4 		$330K Buy
+135,074
New +$316K ﹤0.01% 2206
2021
Q2 		– Sell
-289,018
Closed -$679K – 3207
2021
Q1 		$679K Buy
+289,018
New +$694K 0.01% 1549

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial's LCTX Position: Q2 2026 in Review

HRT Financial sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 232,264 shares — an estimated $366K sold.

HRT Financial first reported a position in LCTX in Q1 2021 and held it in 9 quarters. The position peaked at $1.05M in Q2 2023. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • HRT Financial reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 232,264 Lineage Cell Therapeutics shares in Q2 2026, an estimated $366K.
  • HRT Financial first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 9 quarters.
  • HRT Financial's Lineage Cell Therapeutics position peaked at $1.05M in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.